<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03320187</url>
  </required_header>
  <id_info>
    <org_study_id>OG MS27042017</org_study_id>
    <nct_id>NCT03320187</nct_id>
  </id_info>
  <brief_title>Nitroglycerin Skin Patches for Facilitating Cervical Ripening: A Randomized Controlled Trial</brief_title>
  <official_title>NITROGLYCERINE SKIN PATCH VS PLACEBO PATCH FOR ENHANCING CERVICAL RIPENING IN LABOR INDUCTION: A RANDOMIZED CONTROLLED TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Ahmed S. Abd El-Hameed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prof. Abdel-Megeeed I. Abdel- Megeeed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to establish the efficacy of transdermal glyceryl trinitrate as a nitric
      oxide donor in addition to dinoprostone for induction of cervical ripening in the third
      trimester through progression in the Bishop's score during 24 hour period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: The primary outcome of the study is to compare the changes occurring to the
      cervix through the progression in the Bishop's score between NO donor (nitroglycerine patch)
      vs placebo; in combination with a well-established method of induction (Dinoprostone).

      The secondary objective of the study is to observe and report possible fetal and maternal
      side effects that may be associated. This will establish the safety and tolerability of NO
      donors.

      Research Question: Does the usage of Nitroglycerine skin patch enhance cervical ripening and
      facilitate induction of labor by Dinoprostone?

      Null hypothesis: Nitroglycerine skin patch does not cause advantage for ripening of the
      cervix nor facilitate the process of labor induction.

      Alternative hypothesis : Nitroglycerine skin patch has favorable effect in enhancing cervical
      ripening and the outcome of induction of labor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">September 21, 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the cervical Bishop's score</measure>
    <time_frame>6,12,18 and 24 hours after administration</time_frame>
    <description>progression of Bishop's score recorded twice during the induction of labor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of any fetal or maternal side effects</measure>
    <time_frame>From the time of administration of medication, cases will be assessed every 6 hours till 24 hours after delivery at time of discharge</time_frame>
    <description>associated headache and nausea (for instance) are well-recognized side effects during the induction of labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of Oxytocin to initiate uterine contractions</measure>
    <time_frame>from time of patch administration up to 24 hours</time_frame>
    <description>Whether the case managed to initiate uterine contractions without the need to induce them with oxytocin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitroglycerin as Nitroderm TTSⓇ skin patch is applied on the upper chest alongside with regular induction of labor protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patch is applied on the upper chest alongside with regular induction of labour protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroderm TTS</intervention_name>
    <description>Transdermal nitroglycerin 5mg skin patch</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Nitroglycerin transdermal patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone</intervention_name>
    <description>Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Prostaglandin E2 Analogue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Singleton living full-term fetus.

          2. Cephalic presentation,

          3. Bishop score less than 5,

          4. Assuring fetal monitoring,

          5. The mother does not have PROM,

        Exclusion Criteria:

          1. Expected fetal anomaly (eg. by ultrasound),

          2. Abnormal presentation,

          3. Multiple pregnancy,

          4. Non assuring fetal CTG,

          5. Fetus more than 90th percentile of expected weight,

          6. Previous maternal obstructed labor or previous cesarean section,

          7. Maternal obstetric or medical complication,

          8. Structural anomaly of the uterus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Abdel-Megeeed I. Abdel-Megeeed, Doctorate</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University Maternity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed S. Abd El-Hamid, Doctorate</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University Maternity Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AinShams University Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Sharma Y, Kumar S, Mittal S, Misra R, Dadhwal V. Evaluation of glyceryl trinitrate, misoprostol, and prostaglandin E2 gel for preinduction cervical ripening in term pregnancy. J Obstet Gynaecol Res. 2005 Jun;31(3):210-5.</citation>
    <PMID>15916656</PMID>
  </results_reference>
  <results_reference>
    <citation>Nunes FP, Campos AP, Pedroso SR, Leite CF, Avillez TP, Rodrigues RD, Meirinho M. Intravaginal glyceryl trinitrate and dinoprostone for cervical ripening and induction of labor. Am J Obstet Gynecol. 2006 Apr;194(4):1022-6.</citation>
    <PMID>16580291</PMID>
  </results_reference>
  <results_reference>
    <citation>West HM, Jozwiak M, Dodd JM. Methods of term labour induction for women with a previous caesarean section. Cochrane Database Syst Rev. 2017 Jun 9;6:CD009792. doi: 10.1002/14651858.CD009792.pub3. Review.</citation>
    <PMID>28599068</PMID>
  </results_reference>
  <results_reference>
    <citation>Kelly AJ, Munson C, Minden L. Nitric oxide donors for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD006901. doi: 10.1002/14651858.CD006901.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 05;12 :CD006901.</citation>
    <PMID>21678363</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>Peter Nagy Aziz Hanna</investigator_full_name>
    <investigator_title>Resident Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 4, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

